CY1121087T1 - Παραγωγα ν-αποθειωμενων γλυκοζαμινογλυκανων και χρηση ως φαρμακα - Google Patents

Παραγωγα ν-αποθειωμενων γλυκοζαμινογλυκανων και χρηση ως φαρμακα

Info

Publication number
CY1121087T1
CY1121087T1 CY181100940T CY181100940T CY1121087T1 CY 1121087 T1 CY1121087 T1 CY 1121087T1 CY 181100940 T CY181100940 T CY 181100940T CY 181100940 T CY181100940 T CY 181100940T CY 1121087 T1 CY1121087 T1 CY 1121087T1
Authority
CY
Cyprus
Prior art keywords
glycosaminoglycan
derivatives
desulphurized
invention further
glucosaminoglycans
Prior art date
Application number
CY181100940T
Other languages
English (en)
Inventor
Giangiacomo Torri
Annamaria Naggi
Original Assignee
Novahealth Biosystems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novahealth Biosystems Llc filed Critical Novahealth Biosystems Llc
Publication of CY1121087T1 publication Critical patent/CY1121087T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Η εφεύρεση αφορά σε Ν-αποθειωμένα και προαιρετικώς 2-Ο-αποθειωμένα παράγωγα γλυκοζαμινογλυκάνης, όπου τουλάχιστον τμήμα των γειτονικών διολών και ΟΗ/ΝΗ2 έχουν μετατραπεί προς την αντίστοιχη αλδεΰδη, οι οποίες αλδεΰδες έχουν στη συνέχεια αναχθεί προς την αντίστοιχη αλκοόλη. Αυτά τα προϊόντα είναι προικισμένα με ανασταλτική δραστικότητα ηπαρανάσης και κατά του όγκου δραστικότητα. Τα εν λόγω παράγωγα γλυκοζαμινογλυκάνης λαμβάνονται από φυσική ή συνθετική γλυκοζαμινογλυκάνη, κατά προτίμηση από μη-κλασματωμένη ηπαρίνη, χαμηλού μοριακού βάρους ηπαρίνες (LMWHs), θειική ηπαράνη ή παράγωγα αυτών. Η εφεύρεση περαιτέρω αφορά στη μέθοδο παρασκευής αυτών και περαιτέρω στη χρήση αυτών ως δραστικά συστατικά φαρμάκων, επίσης σε συνδυασμό με γνωστά καθιερωμένα φάρμακα ή θεραπείες. Η παρούσα εφεύρεση περαιτέρω αφορά σε μία μέθοδο για διάσπαση της διασύνδεσης C2-C3 υπολειμμάτων γλυκοζαμίνης μιας γλυκοζαμινογλυκάνης με οξείδωση της εν λόγω γλυκοζαμινογλυκάνης.
CY181100940T 2013-10-31 2018-09-10 Παραγωγα ν-αποθειωμενων γλυκοζαμινογλυκανων και χρηση ως φαρμακα CY1121087T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000005A ITLO20130005A1 (it) 2013-10-31 2013-10-31 Derivati di glucosamminoglicani n-desolfatati e loro uso come farmaci
PCT/EP2014/072707 WO2015062951A1 (en) 2013-10-31 2014-10-23 Derivatives of n-desulfated glucosaminoglycans and use as drugs

Publications (1)

Publication Number Publication Date
CY1121087T1 true CY1121087T1 (el) 2019-12-11

Family

ID=49683857

Family Applications (2)

Application Number Title Priority Date Filing Date
CY181100940T CY1121087T1 (el) 2013-10-31 2018-09-10 Παραγωγα ν-αποθειωμενων γλυκοζαμινογλυκανων και χρηση ως φαρμακα
CY20191100606T CY1121728T1 (el) 2013-10-31 2019-06-07 Παραγωγα ν-αποθειωμενων γλουκοζαμινογλυκανων και χρηση ως φαρμακα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20191100606T CY1121728T1 (el) 2013-10-31 2019-06-07 Παραγωγα ν-αποθειωμενων γλουκοζαμινογλυκανων και χρηση ως φαρμακα

Country Status (14)

Country Link
US (2) US10875936B2 (el)
EP (2) EP3063177B1 (el)
JP (1) JP6753610B2 (el)
KR (1) KR102007554B1 (el)
CN (2) CN105814086B (el)
CY (2) CY1121087T1 (el)
DK (2) DK3375792T3 (el)
ES (2) ES2687900T3 (el)
HK (2) HK1222873A1 (el)
IT (1) ITLO20130005A1 (el)
PL (2) PL3063177T3 (el)
PT (2) PT3375792T (el)
TR (1) TR201908669T4 (el)
WO (1) WO2015062951A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111670038B (zh) * 2018-02-02 2024-01-26 深圳市海普瑞药业集团股份有限公司 糖胺聚糖衍生物及其制备方法和用途
CN111019014A (zh) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 一种那曲肝素钙的制备工艺
WO2021128253A1 (zh) * 2019-12-27 2021-07-01 深圳市海普瑞药业集团股份有限公司 一种糖胺聚糖衍生物及其应用
IT202200014806A1 (it) 2022-07-14 2024-01-14 Centr0 Alta Tecnologia St Di Ricerche Chniche E Bi0Chiniche G Ronzoni S R L Esasaccaridi di sintesi mimetici dell'eparina che mostrano attività di inibizione dell'eparanasi

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230582B (it) 1988-10-21 1991-10-28 Opocrin S P A Lab Farmabiologi Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5583121A (en) * 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
CN1197587C (zh) 2000-06-09 2005-04-20 中国科学院上海细胞生物学研究所 N－位脱硫酸肝素在预防和治疗炎症中的应用
ES2431362T3 (es) 2001-09-12 2013-11-26 Sigma-Tau Research Switzerland S.A. Derivados de glicosaminoglicanos totalmente N-desulfatados como agentes inhibidores de la heparanasa, dotados con actividad antiangiogénica y desprovistos de efecto anticoagulante
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
CN102924627A (zh) 2012-11-19 2013-02-13 江南大学 一种具有抗肿瘤活性的低抗凝肝素的制备方法

Also Published As

Publication number Publication date
TR201908669T4 (tr) 2019-07-22
HK1222873A1 (zh) 2017-07-14
US11248063B2 (en) 2022-02-15
KR102007554B1 (ko) 2019-08-05
CN108912237B (zh) 2021-04-13
US20160237178A1 (en) 2016-08-18
EP3375792B9 (en) 2019-11-13
US10875936B2 (en) 2020-12-29
WO2015062951A1 (en) 2015-05-07
US20210054108A2 (en) 2021-02-25
US20210332162A9 (en) 2021-10-28
CN108912237A (zh) 2018-11-30
HK1254817B (zh) 2020-03-27
CN105814086A (zh) 2016-07-27
ES2687900T3 (es) 2018-10-29
ES2731582T3 (es) 2019-11-18
PT3063177T (pt) 2018-10-19
EP3375792B1 (en) 2019-05-15
ITLO20130005A1 (it) 2015-05-01
DK3063177T3 (en) 2018-10-08
DK3375792T3 (da) 2019-06-24
PT3375792T (pt) 2019-06-27
EP3063177A1 (en) 2016-09-07
EP3375792A1 (en) 2018-09-19
CN105814086B (zh) 2018-09-28
KR20160105969A (ko) 2016-09-08
CY1121728T1 (el) 2020-07-31
JP2017507210A (ja) 2017-03-16
PL3063177T3 (pl) 2018-11-30
US20200216577A1 (en) 2020-07-09
EP3063177B1 (en) 2018-08-15
JP6753610B2 (ja) 2020-09-09
PL3375792T3 (pl) 2019-09-30

Similar Documents

Publication Publication Date Title
CY1121087T1 (el) Παραγωγα ν-αποθειωμενων γλυκοζαμινογλυκανων και χρηση ως φαρμακα
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
CY1120969T1 (el) Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
CY1118157T1 (el) Εκλεκτικοι αναστολεις γλυκοσιδασης και χρησεις αυτων
CY1119487T1 (el) Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα
CY1120885T1 (el) Παραγωγα πυρρολο[3,2-d]πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CY1123581T1 (el) Νεες μεθοδοι για την παραγωγη ολιγονουκλεοτιδιων
BR112016015105A2 (pt) Conjugados var2csa-droga
CY1118900T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
CY1120197T1 (el) Ηπαρινες χαμηλης αντιπηκτικης δρασης
CY1122822T1 (el) Σακχαριτες παραγωγοποιημενοι με κυκλοαλκινιο
CY1116100T1 (el) Παραγωγα πυριμιδινονης, η παρασκευη τους και η φαρμακευτικη τους χρηση
DOP2012000063A (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
CY1121859T1 (el) Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης
CY1121515T1 (el) Μεθοδοι και συνθεσεις για την επουλωση πληγων
CY1121273T1 (el) Παραγωγα 6-αλκυνυλο-πυριδινης ως smac μιμητικα
CU20110088A7 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
CY1121427T1 (el) Χρηση ενος μοριου mir172 για τη μειωση της φλεγμονhς
SMT201600477B (it) Utilizzo di estratti da pelle di coniglio infiammata con virus del vaccino, per la produzione di un farmaco per il trattamento di malattie cerebrovascolari acute
CY1123044T1 (el) Νεες ενωσεις
CY1124814T1 (el) Συμπυκνωμενα παραγωγα ιμιδαζολιου υποκατεστημενα με τριτοταγεις υδροξυ ομαδες ως αναστολεις ρi3κ-γαμμα
BR112018009225A2 (pt) conjugados de anticorpo anti-cd22-maitansina e métodos de uso dos mesmos
BR112012013119A2 (pt) derivados de 1-amino-piperidina-pirrolidina-diona espirocondensada com atividade pesticida.
CY1112058T1 (el) Χρηση των χιτοζανων για την αυξηση του βαθμου αναπτυξης των νυχιων